<DOC>
	<DOCNO>NCT01188148</DOCNO>
	<brief_summary>All participant fulfill follow criterion : age 18 65 year old , domestic Han descendant . Participants randomly assign either ( 1 ) pharmacotherapy ( valproate add-on memantine ) group ; ( 2 ) pharmacotherapy ( valproate add-on memantine ) plus Cognitive Behavior Group Therapy ( CBGT ) group ; ( 3 ) valproate add-on placebo plus CBGT group , ( 4 ) valproate add-on placebo group . A total 240-320 individual ( 60-80 participant per group ) recruit study . For CBGT group , 12-weekly session schedule accord patient ' preference . The investigator attempt understand effect pharmaceutical drug mood stabilizer add-on neuro-protective drug , pharmacotherapy CBGT , mood stabilizer CBGT , use traditional mood stabilizer treatment BP II . Comparisons make type treatment possible mechanism examine regard pharmacotherapy CBGT bipolar disorder patient .</brief_summary>
	<brief_title>Series Studies Bipolar Disorder-Valproate add-on Memantine</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Male female patient age &gt; =18 &lt; = 65 year . 2 . A diagnosis bipolar II disorder accord DSMIVTR criterion make specialist psychiatry . 3 . A total HDRS score least 18 YMRS score least 14 screen . 4 . Signed informed consent patient legal representative . 1 . Women childbearing potential use adequate contraception per investigator judgment willing comply contraception duration study . 2 . Females pregnant nursing . 3 . Patient receive memantine selective cyclooxygenase 2 ( Cox2 ) inhibitor within 1 week prior first dose doubleblind medication . 4 . AxisI DSMIVTR diagnosis bipolar II disorder . 5 . Current evidence uncontrolled and/or clinically significant medical condition ( e.g. , cardiac , hepatic renal failure ) , judgment investigator , would compromise patient safety preclude study participation . 6 . History intolerance valproate memantine Cox2 inhibitor . 7 . History sensitivity reaction ( e.g. , urticaria , angioedema , bronchospasm , severe rhinitis , anaphylactic shock ) precipitate memantine 8 . Patient receive electroconvulsive therapy ( ECT ) within 4 week prior first dose doubleblind medication . 9 . Inclusion another bipolar disorder study study another indication psychotropic 's within last 30 day prior start study . 10 . Increase total SGOT , SGPT , BUN creatinine 3X ULN ( upper limit normal ) . 11 . Substancerelated disorder within 6 month prior study start , borderline personality disorder , schizophrenia , major psychiatric disorder define DSMIV criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>